Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elio Adib

Showing results (41-50 of 44) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 44 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2024
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLCAmin H Nassar, Ritujith Jayakrishnan, Jamie Feng, et al.
JCO Precision Oncology|September 4, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8<sup>+</sup> and PD-1<sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk FactorsJoao V Alessi, James R Lindsay, Anita Giobbie-Hurder, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort StudyAmin H Nassar, So Yeon Kim, Jacqueline V Aredo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2023
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) ConsortiumTalal El Zarif, Amin H Nassar, Elio Adib, et al.
Pageof 5

Showing results (41-50 of 44) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 44 results.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|September 11, 2024
Consolidation ALK Tyrosine Kinase Inhibitors Versus Durvalumab or Observation After Chemoradiation in Unresectable Stage III ALK-Positive NSCLCAmin H Nassar, Ritujith Jayakrishnan, Jamie Feng, et al.
JCO Precision Oncology|September 4, 2025
Immunoprofiling at an Institutional Scale Reveals That High Numbers of Intratumoral CD8<sup>+</sup> and PD-1<sup>+</sup> Cells Predict Superior Patient Survival Across Major Cancer Types Independent of Major Risk FactorsJoao V Alessi, James R Lindsay, Anita Giobbie-Hurder, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 26, 2024
Consolidation Osimertinib Versus Durvalumab Versus Observation After Concurrent Chemoradiation in Unresectable EGFR-Mutant NSCLC: A Multicenter Retrospective Cohort StudyAmin H Nassar, So Yeon Kim, Jacqueline V Aredo, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 16, 2023
Safety and Activity of Immune Checkpoint Inhibitors in People Living With HIV and Cancer: A Real-World Report From the Cancer Therapy Using Checkpoint Inhibitors in People Living With HIV-International (CATCH-IT) ConsortiumTalal El Zarif, Amin H Nassar, Elio Adib, et al.
Pageof 5